Drugs Controller General of India has directed drug regulators of all states and Union Territories to ensure that manufacturers of acidity medicine Ranitidine monitor levels of a potentially cancer-causing impurity in their formulations. They have been told to watch levels of NDMA in the medicine that is commonly available under Aciloc, Rantac and Zinetac brand names.